<DOC>
	<DOCNO>NCT00718549</DOCNO>
	<brief_summary>This study assess effect maintenance treatment MabThera , comparison 2 year observation period ( treatment ) , patient progressive B-cell chronic lymphocytic leukemia previous first-line induction treatment MabThera ( RCC regimen ) .After 6 month induction therapy RCC ( MabThera + cladribine + cyclophosphamide ) patient randomize either receive maintenance treatment MabThera ( 375mg/m2 iv every 12 week , receive treatment ( observation ) .The anticipated time study treatment 2+ year , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Maintenance Treatment With MabThera ( Rituximab ) Patients With Progressive B-cell Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>adult patient , 1875 year age ; confirm diagnosis Bcell chronic lymphocytic leukemia ; stage IIV disease evidence progression ; previous chemotherapy , radiotherapy immunotherapy Bcell chronic lymphocytic leukemia ; ECOG PS 02. active secondary malignancy transformation aggressive lymphoma ; medical condition require chronic use oral corticosteroid dose 1mg/kg 60 mg/m2 2 week ; prior treatment interferon , MabThera another monoclonal antibody , immunosuppressive treatment radiotherapy 12 month study start ; history malignancy within 2 year study entry , except adequately treated cancer situ cervix , basal squamous cell skin cancer , prostate cancer , breast cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>